Moneycontrol
    Moneycontrol PRO

    Jump to

    • No scope of US intervention in Indian pharma cos: Wockhardt

    • Aurobindo's Hyd unit getting form 483 a non-event: Surajit Pal

    • US FDA completes Aurobindo's Unit 4 audit; to help boost US biz

    • Aurobindo's topline can swell by $350 m with Teva buy: PL

    • Lupin to see approvals after US FDA gives clean chit: Macquarie

    • Sun's psoriasis trial drug won't hit mkt before FY19: Analyst

    • 20% of Cipla FY17 revenues to come from US: Chirag Talati

    • Pharma cos facing pricing pressure in US: PhillipCap

    • Sun's margins may reduce to 30-32% post merger: Surajit Pal

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347